Advanced Search

The American Journal of Psychiatry, VOL. 162, No. 9

Letter to the Editor | September 01, 2005

Citalopram and the Curate’s Egg in Geriatric Depression

BERNARD J. CARROLL, M.B.B.S., Ph.D., F.R.C.Psych.

Am J Psychiatry 2005;162:1762-1762. 10.1176/appi.ajp.162.9.1762

Article

References

text A A A

To the Editor:

Bishop: I see you have a bad egg.

Curate: Oh, no, my lord, parts of it are excellent.

The report by Steven P. Roose, M.D., and colleagues on the treatment of old-old depressed patients with citalopram (1) concluded that medication was not more effective than placebo. In this multicenter study, there was a major effect of study site on response and remission rates to both placebo and active drug. Attempting to put the best face on the results, the authors suggested that more severely depressed patients tended to have a higher remission rate with medication. They also underscored the perspective that the placebo condition in such a trial "is not remotely close to a ‘no-treatment’ condition" (p. 2057).

Overall, the trial highlights the present sorry state of research into antidepressant efficacy. A more rigorous view of the data by site suggests that the trial lacked ecological validity. When rates of response and remission are higher for placebo than for active drug at six of nine sites (the authors’ Figure 2), the pooled analysis becomes an exercise in futility. Moreover, the faintly encouraging secondary analyses lacked a sound base in any primary effect, and they were not corrected for multiple comparisons. These concerns are compounded by the multivariate statistical approach, which inflated the practical significance of the secondary analyses.

For instance, in a secondary analysis, the authors reported a significantly higher rate of response (p=0.04) to citalopram versus placebo in the high-severity group (defined by an initial Hamilton Depression Rating Scale score >24). Not only was this "significant" finding not subjected to Bonferroni correction, it did not hold up when the analysis was conducted on the primary outcome data (χ²=3.07, df=1, p<0.08).

Although inflating the trend for citalopram to be more effective in the high-severity group, the authors failed to point out that the low-severity group, in which there was absolutely no suggestion of a drug effect, constituted 61% of the sample. Their data comport with the recent recommendation from the National Institute for Clinical Excellence in Britain that "antidepressants should not be used for the initial treatment of mild depression because the risk-benefit ratio is poor" (2).

As to the authors’ anodyne discussion of the perspective that placebo treatment in a clinical trial amounts to far more than no treatment, the point is so well known that it does not bear tedious repetition and elaboration. It is also irrelevant to the primary objective of the study, which was to determine whether the use of citalopram is associated with added therapeutic value beyond what can be achieved by the attentive clinical interest provided to all patients.

References

Roose SP, Sackeim HA, Krishnan KRR, Pollock BG, Alexopoulos G, Lavretsky H, Katz IR, Hakkarainen H (Old-Old Depression Study Group): Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 2004; 161:2050–2059[PubMed][CrossRef]

National Collaborating Centre for Mental Health: Management of Depression in Primary and Secondary Care: Clinical Guideline 23. London, National Institute for Clinical Excellence, 2004, p 5. http://
www.nice.org.uk/pdf/CG023NICEguideline.pdf

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.

Submit a Comments

Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*

Cancel

Print
PDF
E-mail

Recipient(s) will receive an email with a link (good for 72 hours) to 'Citalopram and the Curate’s Egg in Geriatric Depression' and do not need to have American Journal of Psychiatry account to access the content.
Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*
Separate multiple email address with semi-colons (up to 5).

Subject:* 's American Journal of Psychiatry: 'Citalopram and the Curate’s Egg in Geriatric Depression'
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Processing your request... Please Wait...

Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.

Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation

BERNARD J. CARROLL; Citalopram and the Curate’s Egg in Geriatric Depression. American Journal of Psychiatry. 2005 Sep;162(9):1762-1762.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American Psychiatric Association. All rights reserved.
Reprints